Alvaro Sanchez-Ferro

Alvaro Sanchez-Ferro is a neurologist and cofounder of Leuko, serving as Chief Medical Officer since September 2017, where the focus is on improving care for cancer patients with neutropenia. Currently, Alvaro holds positions as a Movement Disorders Specialist and Principal Investigator at Hospital 12 de Octubre, along with leadership roles in the International Parkinson and Movement Disorder Society as Director and Associate Director of the Clinical Outcomes Program. Alvaro has also contributed as an International Board Editor for the Movement Disorders Journal and chaired the Technology Committee of the Spanish Neurological Society. Previous roles include chairing the Rating Scales Electronic Development Committee at the Movement Disorders Society and serving as CEO at Earlybird Technologies. Education includes a Doctor of Medicine from Universidad Autonoma de Madrid, a PADIIT from IESE Business School, and a Master's in Research Methodology from Universidad Autonoma de Barcelona.